Jury selection underway in Martin Shkreli securities trial

CNBC's Meg Tirrell reports the latest on the Martin Shkreli, the pharmaceuticals executive who gained public infamy by unapologetically hiking the price of a drug by more than 5,000 percent, fraud trial.